Boston Trust Walden’s Axcelis ACLS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACLS
RP
IP
AAIS
SOADOR
LSERS
WB
PM
Boston Trust Walden's ACLS Position: Q2 2026 in Review
Boston Trust Walden reduced its Axcelis (ACLS) stake by 5.1% in Q2 2026, selling an estimated $2.86M and leaving 359,256 shares worth $68.1M. The position accounts for 0.52% of the portfolio, ranked #66.
Boston Trust Walden first reported a position in ACLS in Q3 2024 and has held it in 8 quarters since. 110 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.
- Boston Trust Walden held 359,256 shares of Axcelis worth $68.1M as of Q2 2026.
- Boston Trust Walden sold 19,269 Axcelis shares in Q2 2026, an estimated $2.86M.
- Axcelis made up 0.52% of Boston Trust Walden's portfolio in Q2 2026, its #66 holding.
- Boston Trust Walden first reported a position in Axcelis in Q3 2024 and has held it in 8 quarters since.
- 110 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.
Based on Boston Trust Walden's 13F filing for Q2 2026, filed 24 Jul 2026.